TY - JOUR
T1 - Potential metabolic biomarkers to identify interstitial lung abnormalities
AU - Tan, Yong
AU - Jia, Dongmei
AU - Lin, Zhang
AU - GUO, Baosheng
AU - He, Bing
AU - Lu, Cheng
AU - Xiao, Cheng
AU - Liu, Zhongdi
AU - Zhao, Ning
AU - BIAN, Zhaoxiang
AU - ZHANG, Ge
AU - Zhang, Weidong
AU - Liu, Xinru
AU - LYU, Aiping
N1 - This study was supported by Hong Kong Baptist University Strategic Development Fund (No. SDF13-1209-P01), Interdisciplinary Research Matching Scheme (IRMS) of Hong Kong Baptist University (No. RC-IRMS/12-13/02), E-Institutes of Shanghai Municipal Education Commission (No. E03008), Professor of Chang Jiang Scholars Program, National Natural Science Foundation of China (No. 81230090, 81520108030, 81573318, 81373301, and 1302658), Shanghai Engineering Research Center for the Preparation of Bioactive Natural
Products (No. 10DZ2251300), Scientific Foundation of Shanghai China (No. 12401900801 and 13401900101),
National Major Project of China (No. 2011ZX09307-002-03) and National Key Technology R & D Program of China (No. 2012BAI29B06).
Publisher Copyright:
© 2016 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2016/7/16
Y1 - 2016/7/16
N2 - Determining sensitive biomarkers in the peripheral blood to identify interstitial lung abnormalities (ILAs) is essential for the simple early diagnosis of ILAs. This study aimed to determine serum metabolic biomarkers of ILAs and the corresponding pathogenesis. Three groups of subjects undergoing health screening, including healthy subjects, subjects with ILAs, and subjects who were healthy initially and with ILAs one year later (Healthy→ILAs), were recruited for this study. The metabolic profiles of all of the subjects’ serum were analyzed by liquid chromatography quadruple time-of-flight mass spectrometry. The metabolic characteristics of the ILAs subjects were discovered, and the corresponding biomarkers were predicted. The metabolomic data from the Healthy→ILAs subjects were collected for further verification. The results indicated that five serum metabolite alterations (up-regulated phosphatidylcholine, phosphatidic acid, betaine aldehyde and phosphatidylethanolamine, as well as down-regulated 1-acylglycerophosphocholine) were sensitive and reliable biomarkers for identifying ILAs. Perturbation of the corresponding biological pathways (RhoA signaling, mTOR/P70S6K signaling and phospholipase C signaling) might be at least partially responsible for the pathogenesis of ILAs. This study may provide a good template for determining the early diagnostic markers of subclinical disease status and for obtaining a better understanding of their pathogenesis.
AB - Determining sensitive biomarkers in the peripheral blood to identify interstitial lung abnormalities (ILAs) is essential for the simple early diagnosis of ILAs. This study aimed to determine serum metabolic biomarkers of ILAs and the corresponding pathogenesis. Three groups of subjects undergoing health screening, including healthy subjects, subjects with ILAs, and subjects who were healthy initially and with ILAs one year later (Healthy→ILAs), were recruited for this study. The metabolic profiles of all of the subjects’ serum were analyzed by liquid chromatography quadruple time-of-flight mass spectrometry. The metabolic characteristics of the ILAs subjects were discovered, and the corresponding biomarkers were predicted. The metabolomic data from the Healthy→ILAs subjects were collected for further verification. The results indicated that five serum metabolite alterations (up-regulated phosphatidylcholine, phosphatidic acid, betaine aldehyde and phosphatidylethanolamine, as well as down-regulated 1-acylglycerophosphocholine) were sensitive and reliable biomarkers for identifying ILAs. Perturbation of the corresponding biological pathways (RhoA signaling, mTOR/P70S6K signaling and phospholipase C signaling) might be at least partially responsible for the pathogenesis of ILAs. This study may provide a good template for determining the early diagnostic markers of subclinical disease status and for obtaining a better understanding of their pathogenesis.
KW - Biomarkers
KW - Interstitial lung abnormalities
KW - Serum metabolic profiles
UR - http://www.scopus.com/inward/record.url?scp=84978743392&partnerID=8YFLogxK
U2 - 10.3390/ijms17071148
DO - 10.3390/ijms17071148
M3 - Journal article
C2 - 27438829
AN - SCOPUS:84978743392
SN - 1661-6596
VL - 17
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 7
M1 - 1148
ER -